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Introduction {#sec1}
============

Intracellular deoxyribonucleoside triphosphate (dNTP) concentrations are controlled by dNTP synthesis and degradation. dNTPs are supplied by two pathways known as *de novo* and salvage. In the *de novo* pathway, dNTPs are synthesized from intracellular precursors. The enzyme ribonucleotide reductase catalyzes the rate-limiting step and converts ribonucleoside diphosphates into deoxyribonucleoside (dN) diphosphates ([@bib38]). The salvage pathway involves uptake of dNs from the extracellular environment, followed by intracellular phosphorylation by cytosolic and mitochondrial kinases to form dNTPs ([@bib22], [@bib42], [@bib70]).

One enzyme that degrades intracellular dNTPs is the phosphohydrolase SAMHD1, initially identified as an interferon γ-inducible transcript in dendritic cells ([@bib55]). SAMHD1 cleaves all four dNTPs into the corresponding dNs and inorganic triphosphate ([@bib30], [@bib67]). The catalytically active form of the protein is a homo-tetramer, the formation of which is regulated allosterically by dNTPs and guanosine triphosphate (GTP) as well as by phosphorylation of threonine 592 (reviewed in [@bib1], [@bib9]). SAMHD1 has been studied extensively in the context of human immunodeficiency virus (HIV) infection. By limiting the supply of dNTPs for the viral reverse transcriptase, SAMHD1 blocks HIV infection in certain cell types ([@bib41], [@bib50], [@bib51], [@bib69]). *SAMHD1* mutations cause Aicardi-Goutières syndrome (AGS), a rare autoinflammatory disease characterized by chronic production of type I interferons, a family of cytokines typically upregulated only during acute virus infection ([@bib18], [@bib73]). Furthermore, mutations in the *SAMHD1* gene have been found in several types of cancer, including colorectal cancer and leukemias ([@bib16], [@bib44], [@bib52], [@bib71], [@bib79]). It is possible that inactivation of SAMHD1 provides transformed cells with a growth advantage simply due to elevated dNTP levels. Alternatively, the role of SAMHD1 in cancer may relate to its functions in DNA repair and DNA replication, which are independent of dNTP degradation ([@bib16], [@bib17], [@bib19]).

Chronic lymphocytic leukemia (CLL) is a very common form of adult leukemia and affects the elderly ([@bib81]). Refractoriness to chemotherapy and relapse remain major causes of death for patients with CLL. Nucleotide metabolism is an attractive target for the treatment of CLL and other leukemias. The small molecule forodesine (also known as Immucillin H or BCX-1777) was developed to inhibit purine nucleoside phosphorylase (PNP) ([@bib45]). PNP degrades deoxyguanosine (dG) into guanine, which is further catabolized into uric acid, which is released by cells ([@bib26]). dG has cytotoxic properties ([@bib20], [@bib57], [@bib82]), and genetic PNP deficiency causes immunodeficiency and results in the loss of T cells and, in some patients, also affects B cell function ([@bib58]). Upon forodesine treatment, dG accumulates intracellularly and is phosphorylated to deoxyguanosine triphosphate (dGTP). The resulting imbalance in dNTP pools is predicted to cause cell death and eliminate leukemic cells ([@bib10]). Furthermore, the synergy between dG and forodesine in inducing cell death *in vitro* has been suggested ([@bib11]), and, in patients, forodesine treatment increases plasma dG levels ([@bib5], [@bib6]). Forodesine showed promising results *in vitro* in killing CLL B cells; surprisingly, however, it had substantial activity only in a small subset of patients with B or T cell malignancies ([@bib2], [@bib5], [@bib6], [@bib21], [@bib27], [@bib28], [@bib59]).

Here, we explore the role of SAMHD1 in dNTP metabolism. We report that SAMHD1 protected cells against imbalances in dNTP pools. In cells lacking SAMHD1, engagement of the salvage pathway resulted in programmed cell death. Exposure to dG was particularly potent at inducing intrinsic apoptosis in SAMHD1-deficient primary and transformed cells. We further show that forodesine and other PNP inhibitors acted synergistically with dG to induce death in cells lacking SAMHD1. Importantly, *SAMHD1*-mutated leukemic cells without SAMHD1 expression from patients with CLL were selectively killed by forodesine and dG. This showed that SAMHD1 was limiting the potency of forodesine. It may therefore be possible to stratify patients with leukemia for forodesine treatment by *SAMHD1* genotype or expression.

Results {#sec2}
=======

SAMHD1 Protects Cells against dNTP Overload {#sec2.1}
-------------------------------------------

To investigate the role of SAMHD1 in dNTP metabolism, we added equimolar concentrations of dNs to wild-type (WT) or SAMHD1-deficient cells. Surprisingly, widespread cell death was apparent by brightfield microscopy in cells lacking SAMHD1, but not in control cells after overnight incubation with dNs (data not shown). To study this phenotype systematically, we analyzed mouse embryonic fibroblasts (MEFs), mouse bone-marrow-derived macrophages (BMDMs), and primary human fibroblasts. Cell viability was assessed using a luminescence-based assay for intracellular ATP levels (CellTiter-Glo). We observed reduced viability of dN-exposed *Samhd1*^*−/−*^ MEFs and BMDMs and human fibroblasts from a patient with AGS homozygously carrying the Q149X nonsense mutation in *SAMHD1* ([Figure 1](#fig1){ref-type="fig"}A). The viability of WT mouse and control human cells, including fibroblasts from patients with AGS carrying other AGS-causing mutations in *IFIH1* or *ADAR1*, was largely unaltered after the addition of dNs. To confirm that the absence of SAMHD1 renders cells susceptible to dN-induced cell death, we reconstituted BMDMs with a retrovirus expressing mouse SAMHD1. Indeed, expression of SAMHD1 in *Samhd1*^*−/−*^ cells rescued viability after treatment with dNs ([Figures 1](#fig1){ref-type="fig"}B and 1C).Figure 1Deoxyribonucleosides (dNs) Are Toxic in SAMHD1-Deficient Cells(A) Mouse embryonic fibroblasts (MEFs), BMDMs, and AGS patient-derived fibroblasts were treated with a mix of all four dNs. MEFs were cultured with 0.8 mM of each dN for 48 h. BMDMs and fibroblasts were treated with 0.5 mM of each dN for 24 h. Cell viability was determined by CellTiter-Glo assay. For each genotype, values from untreated control cells were set to 100%. Data from triplicate measurements are shown with mean ± SD. p values determined with unpaired t tests (MEFs and BMDMs) or one-way ANOVA (fibroblasts) are indicated.(B and C) SAMHD1 expression was reconstituted in *Samhd1*^*−/−*^ BMDMs. Cells of the indicated genotype were infected with a retrovirus expressing SAMHD1 or empty control retrovirus. Cells were then treated with 0.5 mM of each dN for 24 h. (B) Cell viability was tested as in (A). Values from triplicate measurements are shown with mean ± SD. p values determined with two-way ANOVA are indicated. (C) SAMHD1 expression was tested by western blot in BMDMs from three mice per genotype. β-Actin served as a loading control.(D) BMDMs were treated with equimolar concentrations of all four dNs or with individual dNs at the indicated concentrations for 24 h. Cell viability was tested as in (A). Data from biological triplicates are shown as mean ± SEM.(E) BMDMs were treated with individual dNs and combinations of dNs. Cells were cultured with 0.5 mM of the indicated dN(s) for 24 h, and viability was analyzed as in (A). Data from biological triplicates were averaged and are represented as a heatmap.(F) BMDMs were treated with 0.5 mM dG for 24 h. Brightfield images are shown. Scale bar represents 300 μm.(G) BMDMs were treated with increasing doses of dG for 24 h and fixed and stained with crystal violet. The wedge denotes 0.2, 0.4, 0.8, and 1.6 mM dG; NT, not treated.(H) BMDMs were treated with 0.4 mM dG. Viability was monitored with the cell-impermeable dye Yoyo3 for 24 h using an in-incubator imaging system (Incucyte). Yoyo3^+^ cells were enumerated. Mean values from triplicate measurements are shown ± SD.(I and J) BMDMs (I) and MEFs (J) were treated with 0.5 mM dG for 2 h, and intracellular dNTP levels were quantified relative to NTP levels. Data from three biological replicates are shown together with mean ± SEM. The p values determined with two-way ANOVA are indicated.(A)--(C) and (F)--(H) are representative of at least three independent experiments. ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001.

Next, we exposed BMDMs to increasing concentrations of dNs. We observed dose-dependent toxicity in *Samhd1*^*−/−*^ cells, but not in WT cells, starting at ∼0.1 mM dNs ([Figure 1](#fig1){ref-type="fig"}D). To determine if this effect was due to a specific dN, we treated BMDMs with single dNs. Interestingly, the highest toxicity in *Samhd1*^*−/−*^ cells was observed when dG was used ([Figure 1](#fig1){ref-type="fig"}D). Like dG treatment, deoxyadenonsine (dA) also reduced viability specifically in SAMHD1-deficient cells, but at higher doses: a 50% reduction in intracellular ATP levels was observed with ∼0.1 mM dG and ∼1 mM dA ([Figure 1](#fig1){ref-type="fig"}D). Of note, dG also caused toxicity in WT cells at high doses above 5 mM ([Figure 1](#fig1){ref-type="fig"}D). We also tested dN combinations using a fixed dose of 0.5 mM. dG was the most toxic dN in *Samhd1*^*−/−*^ cells when used alone or in combination with dA and/or thymidine, while the presence of deoxycytidine (dC) reduced the effect of dG on cell viability ([Figure 1](#fig1){ref-type="fig"}E). We therefore focused on dG in subsequent experiments at doses that did not reduce viability in WT cells. Brightfield images, crystal violet staining, and live-cell imaging confirmed the toxicity of dG in *Samhd1*^*−/−*^ cells ([Figures 1](#fig1){ref-type="fig"}F--1H). In line with earlier work ([@bib13], [@bib69]), the measurement of intracellular dNTP concentrations showed that the levels of all four dNTPs were elevated in *Samhd1*^*−/−*^ cells ([Figures 1](#fig1){ref-type="fig"}I and 1J). Importantly, dG treatment resulted in 46-fold and 6-fold increases in dGTP concentrations in *Samhd1*^*−/−*^ BMDMs and MEFs, respectively, while dGTP levels stayed largely unchanged in WT cells ([Figures 1](#fig1){ref-type="fig"}I and 1J). Taken together, these data show that exposure to dG led to dGTP accumulation in cells lacking SAMHD1, subsequently resulting in cell death.

dG Treatment Induces Apoptosis in *Samhd1*^*−/−*^ Cells {#sec2.2}
-------------------------------------------------------

We next determined the type of cell death triggered by dNs in *Samhd1*^*−/−*^ cells. Annexin V and 7-aminoactinomycin D (7AAD) staining showed an increased frequency of early apoptotic (AnnexinV^+^7AAD^−^) and dead (AnnexinV^+^7AAD^+^) cells in dN-treated *Samhd1*^*−/−*^ BMDM cultures ([Figure 2](#fig2){ref-type="fig"}A). Using the Caspase-Glo assay to measure the activity of apoptotic caspases, we found that the addition of dG to *Samhd1*^*−/−*^ BMDMs, but not to WT cells, activated caspase 3/7 ([Figure 2](#fig2){ref-type="fig"}B). Live-cell imaging revealed that *Samhd1*^*−/−*^ BMDMs treated with dG stained positive for Annexin V around 5 h post-treatment and subsequently for propidium iodide (PI) ([Figure 2](#fig2){ref-type="fig"}C). These observations suggest that dG treatment induced apoptosis, followed by secondary necrosis, rendering cells permeable to PI. Quantification of AnnexinV^+^PI^+^ cells by microscopy 24 h after dG exposure affirmed increased levels of dead *Samhd1*^*−/−*^ BMDMs ([Figure 2](#fig2){ref-type="fig"}D). Cleaved caspase 3 was detectable by western blot in *Samhd1*^*−/−*^, but not WT, BMDMs, supporting the notion that dG induced apoptosis ([Figure 2](#fig2){ref-type="fig"}E). Cycloheximide (CHX) served as a control in these experiments and induced caspase 3 cleavage in WT and *Samhd1*^*−/−*^ cells. Cytochrome C is normally present in mitochondria and released into the cytosol early during intrinsic apoptosis. To characterize the apoptosis pathway activated by dG treatment, we measured cytochrome C levels in the cytosol and found that treatment of *Samhd1*^*−/−*^ BMDMs with dG led to a redistribution of cytochrome C into the cytosol ([Figure 2](#fig2){ref-type="fig"}F). To investigate whether a soluble factor was triggering apoptosis, we co-cultured WT and *Samhd1*^*−/−*^ BMDMs and treated them with dG. Viability decreased with increasing proportions of *Samhd1*^*−/−*^ cells present in the co-culture, suggesting that apoptosis was induced in a cell-autonomous fashion ([Figure 2](#fig2){ref-type="fig"}G). Altogether, these results show that dG triggered intrinsic apoptosis in *Samhd1*^*−/−*^ cells.Figure 2dG Treatment Kills *Samhd1*^*−/−*^ Cells by Apoptosis(A) BMDMs were treated with 0.5 mM of each dN for 24 h and stained with Annexin V and 7AAD. AnnexinV^+^7AAD^−^ and AnnexinV^+^7AAD^+^ cells were quantified by flow cytometry. Data from triplicate measurements are shown with mean ± SD. p values determined with two-way ANOVA are indicated.(B) Caspase activity was assessed in BMDMs 6 h after treatment with the indicated doses of dG, or Staurosporine as control, using the Caspase 3/7 Glo assay. For each genotype, values from untreated control cells were set to 100. Data from triplicate measurements are shown with mean ± SD. The p value determined with an unpaired t test is indicated.(C and D) Live-cell imaging of *Samhd1*^*−/−*^ BMDMs treated with 0.5 mM dG. Alexa 488-labeled Annexin V and propidium iodide (PI) were added to the culture medium to visualize early apoptotic cells and cells that lost membrane integrity, respectively.(C) Representative images of a *Samhd1*^*−/−*^ cell treated with dG. Numbers show the time after dG exposure (h:min).(D) Enumeration of AnnexinV^+^ PI^+^ cells after 24 h of treatment with or without 0.5 mM dG. Six images per condition were analyzed, and means ± SEM are shown. The p value determined with an unpaired t test is indicated.(E and F) BMDMs were treated with 0.5 mM dG or 1 μg/mL cycloheximide (CHX, added to WT cells in F) for 8 hours.(E) Levels of the indicated proteins in total cell extracts were determined by western blot.(F) Cells were fractionated into cytosol and a pellet containing organelles. Levels of the indicated proteins were determined by western blot. β-Actin served as a loading control.(G) WT and *Samhd1*^*−/−*^ BMDMs were co-cultured at the indicated ratios. Cell viability was determined as in [Figure 1](#fig1){ref-type="fig"}A 24 h after treatment with 0.5 mM dG. Data from triplicate measurements are shown with mean ± SD.(A)--(G) are representative of at least three independent experiments. ns, p ≥ 0.05; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Nuclear DNA Replication Is Not Required for dG-Induced Apoptosis {#sec2.3}
----------------------------------------------------------------

Earlier work in yeast showed that severe dNTP pool imbalances can trigger stalled replication forks and checkpoint activation ([@bib48], [@bib65]). To study the role of DNA replication in dG-induced death of SAMHD1-deficient cells, we analyzed cell cycle progression in BMDMs by BrdU and PI staining after dG treatment. Untreated WT and *Samhd1*^*−/−*^ BMDM cultures contained ∼20% BrdU^+^ cells, indicative of cells in S-phase with ongoing DNA replication ([Figure S1](#mmc1){ref-type="supplementary-material"}A). After dG treatment, WT cells already in S-phase progressed through the cell cycle. At the same time, new cells did not enter S-phase, resulting in a much reduced population of BrdU^+^ cells after 24 h of dG exposure. In contrast, *Samhd1*^*−/−*^ cells in S-phase did not progress. Instead, a population of cells displaying sub-G0/G1 PI staining, indicative of dead cells that lost their nucleic acid content, was detected in *Samhd1*^*−/−*^ cultures, starting at 8 h after dG treatment ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Next, we performed a BrdU pulse-chase experiment in which we labeled BMDMs with BrdU first and then treated with dG. Over time, WT cultures accumulated a distinct population of G0/G1-BrdU^+^ cells and contained fewer cells in S-phase ([Figure S1](#mmc1){ref-type="supplementary-material"}B). This confirmed that WT cells progressed through the cell cycle but did not enter S-phase. In *Samhd1*^*−/−*^ cultures, cells with sub-G0/G1 PI staining were evident from 8 h onward. These included both BrdU^+^ and BrdU^−^ cells, suggesting that dG treatment killed both cycling and non-cycling *Samhd1*^*−/−*^ cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B). We therefore tested whether DNA replication was required for the toxicity of dG in *Samhd1*^*−/−*^ cells. BMDMs were cultured in serum-free medium (R0) or pre-treated with hydroxyurea (HU), both of which induced cell cycle arrest, evident from reduced numbers of cells in S-phase ([Figure S1](#mmc1){ref-type="supplementary-material"}C). *Samhd1*^*−/−*^ cells arrested by both methods were susceptible to killing by dG ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). We also pre-treated BMDMs with aphidicolin (APD), which blocks nuclear, but not mitochondrial, DNA polymerases ([@bib53], [@bib84]). As expected, APD-treated cells were arrested in early S-phase ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Interestingly, APD-treated *Samhd1*^*−/−*^ cells were susceptible to dG-induced toxicity ([Figure S1](#mmc1){ref-type="supplementary-material"}G). Finally, we assessed oxidative stress by measuring levels of the reactive oxygen species H~2~O~2~ and found that dG treatment of WT and SAMHD1-deficient BMDMs did not induce oxidative stress ([Figure S1](#mmc1){ref-type="supplementary-material"}H). As a control, we used menadione that induced equivalent H~2~O~2~ levels in cells irrespective of their genotype. Together, these data suggest that dG-induced apoptosis occurred independently of nuclear DNA replication and oxidative stress and that dGTP overload was toxic in both cycling and non-cycling *Samhd1*^*−/−*^ cells.

dG Treatment Kills SAMHD1-Deficient Cancer Cells {#sec2.4}
------------------------------------------------

*SAMHD1* mutations are present in several types of cancer and, in many cases, result in reduced mRNA and protein levels ([@bib16], [@bib44], [@bib71]). We therefore wished to explore our finding of dN-induced cell death in the context of malignant disease. Initially, we tested cancer cell lines. Vpx is a HIV-2 accessory protein that targets SAMHD1 for proteasomal degradation ([@bib41], [@bib50]). We used virus-like particles (VLPs) containing Vpx to deplete SAMHD1 in the cervical cancer cell line HeLa and the breast cancer cell line MDA-MB231, which both express SAMHD1. Cells treated with VLP~vpx~, but not with control VLPs lacking Vpx (VLP~ctrl~), showed reduced viability upon addition of dNs or dG ([Figures 3](#fig3){ref-type="fig"}A--3D). SAMHD1 staining and analysis by flow cytometry or SAMHD1 western blot showed SAMHD1 depletion using VLP~vpx~ in HeLa and MDA-MB231 cells, respectively ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C). In addition, we generated a *Samhd1*^*−/−*^ B16F10 mouse melanoma cell line using CRISPR-Cas9 (strategy and validation shown in [Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E). *Samhd1*^*−/−*^ B16F10 cells showed increased frequencies of early apoptotic (AnnexinV^+^7AAD^−^) and dead (AnnexinV^+^7AAD^+^) cells upon dG treatment, accompanied by reduced confluency ([Figures 3](#fig3){ref-type="fig"}E--3G and [S2](#mmc1){ref-type="supplementary-material"}F). We made similar observations in the murine colorectal cancer cell line CT26 upon SAMHD1 knockout (data not shown). We also included Jurkat cells in our analysis, a human T cell line that, in contrast to the other cell lines utilized, does not express SAMHD1 ([@bib8]). Jurkat cells were exquisitely sensitive to dG treatment at doses approximately 10 times lower than those used in most other experiments ([Figure 3](#fig3){ref-type="fig"}H). We confirmed the killing of Jurkat cells by testing their clonogenic potential, which was greatly reduced upon dG treatment ([Figure 3](#fig3){ref-type="fig"}I). Reconstitution with a lentivirus expressing human SAMHD1 partially rescued viability upon dG treatment ([Figures 3](#fig3){ref-type="fig"}J and 3K). Interestingly, SAMHD1 K11A, which does not localize to the cell nucleus but remains active as a dNTPase ([@bib76]), executed an even more pronounced rescue as compared to WT SAMHD1 ([Figures 3](#fig3){ref-type="fig"}J and 3K). In contrast, SAMHD1 H233A, which lacks catalytic activity, was largely defective in rescuing viability upon dG treatment ([Figure S3](#mmc1){ref-type="supplementary-material"}). In conclusion, SAMHD1 protected cancer cell lines against dN-triggered toxicity.Figure 3dG Induces the Death of Cancer Cell Lines(A) HeLa cells were infected with VLPs containing Vpx (VLP~vpx~) or not (VLP~ctrl~). After 24 h, cells were treated with 0.5 mM of each dN for an additional 24 h. Cell viability was assessed as in [Figure 1](#fig1){ref-type="fig"}A.(B and C) HeLa (B) and MDA-MB231 (C) cells were left uninfected (NI) or were infected with VLPs containing Vpx (VLP~vpx~) or not (VLP~ctrl~). After 24 h, cells were treated with 0.5 mM dG, and brightfield images were acquired after an additional 10--12 h. Scale bars represent 300 μm.(D) MDA-MB231 cells were treated as in (C), and confluency was monitored after dG addition using a live-cell imaging system in the incubator (Incucyte). The mean of 9 measurements ± SD is shown.(E--G) Wild-type and *Samhd1*^*−/−*^ B16F10 cells were treated with dG as indicated for 20 h.(E and F) Cells were then stained with Annexin V and 7AAD and analyzed by flow cytometry. Representative fluorescence-activated cell sorting (FACS) plots are shown in (E), and Annexin V^+^ 7AAD^−^ and Annexin V^+^ 7AAD^+^ cells were quantified in (F).(G) Confluency was determined as in (D).(H) Jurkat cells were treated for 20 h with dG as indicated or with 25 μM etoposide. Cell viability was determined as in [Figure 1](#fig1){ref-type="fig"}A.(I) Jurkat cells were treated with dG as indicated for 20 h and then seeded in semi-solid medium containing dG. After 13 days, cell colonies were counted, and the number colonies per field of view are shown.(J and K) Jurkat cells were reconstituted with hemagglutinin (HA)-tagged wild-type or K11A mutant SAMHD1 using a lentivector. Uninfected cells (NI) served as control.(J) Cells were then treated with dG for 48 h. Cell viability was determined as in [Figure 1](#fig1){ref-type="fig"}A.(K) SAMHD1 levels in total cell extracts were determined by western blot. β-Actin served as a loading control.(A), (D)--(H), and (J)--(K) are representative of three independent experiments and (B) and (C) of two experiments. In (A), (F)--(H), and (J), dots represent technical triplicates and means ± SD are shown. In (I), data from two independent experiments were pooled, and dots represent the mean of technical duplicates per experiment. The p values determined with two-way ANOVA are indicated. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001.See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [3](#mmc1){ref-type="supplementary-material"}.

SAMHD1 Protects against Combined Forodesine and dG Treatment {#sec2.5}
------------------------------------------------------------

Forodesine is an inhibitor of PNP, which converts dG into guanine and α-D-ribose 1-phosphate, and has been shown to induce apoptosis in leukemic cells, possibly by increasing the intracellular and plasma concentrations of dG and consequently intracellular dGTP ([@bib6], [@bib12], [@bib45], [@bib66]). Our system, in which SAMHD1-deficient cells fed with dG died by apoptosis due to dGTP overload, resembled this situation. We therefore hypothesized that forodesine and dG might work synergistically in SAMHD1-deficient cells. Indeed, low doses of dG or forodesine alone did not compromise the viability of WT or *Samhd1*^*−/−*^ BMDMs, while the combination of both was toxic in *Samhd1*^*−/−*^ cells ([Figures 4](#fig4){ref-type="fig"}A, and 4B). We confirmed this observation using 10 μM dG and 1 μM forodesine at (1) different time points, (2) with crystal violet staining, and (3) biochemically by cleavage of poly (ADP-ribose) polymerase (PARP) and CASPASE3 ([Figures 4](#fig4){ref-type="fig"}C--4F). Jurkat cells treated with the same doses of forodesine and dG showed increased proportions of AnnexinV^+^7AAD^−^ cells, and this was prevented when SAMHD1 or SAMHD1 K11A were expressed ([Figures 4](#fig4){ref-type="fig"}G--4I). On the other hand, SAMHD1-sufficient HeLa cells were sensitized to combined forodesine and dG treatment by Vpx-mediated depletion of SAMHD1 ([Figure 4](#fig4){ref-type="fig"}J).Figure 4PNP Inhibitors and dG Synergistically Induce Cell Death in Cells Lacking SAMHD1(A--C) BMDMs were treated with the indicated doses of dG and forodesine. Viability was tested as in [Figure 1](#fig1){ref-type="fig"}A after 24 or 48 h.(D) BMDMs treated for 24 h with dG and forodesine were fixed and stained with crystal violet. After washing, cell-associated dye was solubilized and quantified by absorbance at 570 nm. For each genotype, values from untreated control cells were set to 100%.(E and F) BMDMs were treated for 8 h with dG and forodesine. Levels of PARP and cleaved PARP (E) or cleaved CASPASE 3 and SAMHD1 (F) in total cell extracts were determined by western blot. β-Actin served as a loading control. cld, cleaved.(G--I) Jurkat cells were reconstituted with SAMHD1 as described in [Figures 3](#fig3){ref-type="fig"}J and 3K. Uninfected cells (NI) served as control.(G and H) Cells were treated for 18 h with 10 μM dG and 1 μM forodesine. Cells were then stained with Annexin V and 7AAD and analyzed by flow cytometry. Representative FACS plots are shown in (G) and Annexin V^+^ 7AAD^−^ cells are quantified in (H).(I) SAMDH1 levels in total cell extracts were determined by western blot. β-Actin served as a loading control.(J) HeLa cells were infected with VLPs containing Vpx (VLP~vpx~) or not (VLP~ctrl~). After 6 h, cells were treated with 20 μM dG and 2 μM forodesine, and brightfield images were acquired after an additional 48 h. Scale bar represents 300 μm.(K) BMDMs were treated with the indicated doses of dG and forodesine. Viability was tested as in [Figure 1](#fig1){ref-type="fig"}A after 24 h. Means from three biological replicates are shown ± SEM.(L) *Samhd1*^*−/−*^ BMDMs were treated with the indicated doses of dG in the presence or absence of 1 μM forodesine. Cell viability was determined by CellTiter-Glo assay after 24 h. Data were normalized by setting the values for the lowest and highest dG concentrations to 100 and 0, respectively. Means from three biological replicates are shown ± SEM. Half maximal inhibitory concentration (IC~50~ ) values were calculated from the non-linear regression curves shown on the graph.(M and N) BMDMs were treated with the indicated doses of dG and homo-DFPP-DG (M) or 6C-DFPP-DG (N). Viability was tested as in [Figure 1](#fig1){ref-type="fig"}A after 24 h.Data are representative of three independent experiments. In (A)--(D), (M), (N), and (H), dots represent BMDMs from individual mice and technical replicates, respectively. Mean ± SD is shown. The p values determined with two-way ANOVA are indicated. ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001

To further study the synergy between forodesine and dG in cells lacking SAMHD1, we titrated forodesine and dG. Forodesine alone had no effect on the viability of *Samhd1*^*−/−*^ BMDMs, including at high doses ([Figure 4](#fig4){ref-type="fig"}K, closed symbols). In contrast, dG triggered dose-dependent toxicity in the presence of 1 μM forodesine in *Samhd1*^*−/−*^ cells, but not in WT cells ([Figure 4](#fig4){ref-type="fig"}K, open symbols). Comparing the dose response to dG in the presence or absence of forodesine revealed that forodesine sensitized SAMHD1-deficient BMDMs to dG by approximately 10-fold ([Figure 4](#fig4){ref-type="fig"}L).

Finally, we tested whether other PNP inhibitors might induce death of SAMHD1-deficient cells in the presence of dG. Indeed, BMDMs showed reduced viability upon exposure to either homo-DFPP-DG or 6C-DFPP-DG ([@bib29], [@bib36], [@bib37]) together with low doses of dG ([Figures 4](#fig4){ref-type="fig"}M and 4N). Taken together, these data show that SAMHD1 protected cells against death that was synergistically induced by PNP inhibitors and dG. Thus, our observations reveal a key role of SAMHD1 in the mechanism underlying the toxicity of compounds such as forodesine.

CLL B Cells with *SAMHD1* Mutations Are Highly Sensitive to a Combination Treatment of Forodesine and dG {#sec2.6}
--------------------------------------------------------------------------------------------------------

*SAMHD1* is mutated in 11% of patients with refractory CLL ([@bib16]). Since SAMHD1 protected cells against treatment with forodesine and dG ([Figure 4](#fig4){ref-type="fig"}), we hypothesized that CLL B cells with *SAMHD1* mutations would be particularly susceptible to this combination treatment. To test this, we compared the effect of forodesine and dG treatment on peripheral blood mononuclear cells (PBMCs) from patients with CLL with or without acquired mutations in *SAMHD1*.

Details of the genetic status and *SAMHD1* mutations of the patients' cells are shown in [Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B. PBMCs from patients with CLL were treated with 2 μM forodesine, 20 μM dG, or both. When used alone, neither forodesine nor dG significantly reduced cell viability assessed by intracellular ATP content ([Figure 5](#fig5){ref-type="fig"}A). The combination of both compounds had little effect on the viability of PBMCs from patients without *SAMHD1* mutations. However, significantly reduced PBMC viability was observed in the *SAMHD1*-mutated group ([Figure 5](#fig5){ref-type="fig"}A). These data were confirmed by flow cytometry: the population of live cells was selectively reduced after forodesine and dG treatment of PBMCs from patients with *SAMHD1* mutations (data not shown).Figure 5Elimination of *SAMHD1*-Mutated Leukemic Cells by Forodesine and dG Treatment(A) PBMCs from patients with CLL were treated for 24 h with dG and forodesine as indicated. Viability was tested as in [Figure 1](#fig1){ref-type="fig"}A. Details on *SAMHD1* genetic status are provided in [Figures S4](#mmc1){ref-type="supplementary-material"}A and 4B.(B--H) PBMCs from healthy control subjects and patients with CLL were treated or not for 24 h with 20 μM dG and 2 μM forodesine (Foro + dG). Cells were then analyzed using CyTOF.(B) Live cells were gated (see [Figure S4](#mmc1){ref-type="supplementary-material"}C). The CD5 and CD19 staining is shown for selected samples (see [Figure S4](#mmc1){ref-type="supplementary-material"}D for all samples).(C) Percentages of untreated, live CD5^+^CD19^+^ cells are shown.(D) SAMHD1 expression was analyzed in untreated, live CD5^+^CD19^+^ cells, and the percentage of SAMHD1^+^ cells is shown (see [Figure S4](#mmc1){ref-type="supplementary-material"}C for gating).(E) Live CD5^+^CD19^+^ cells from each sample were analyzed separately by viSNE using 22 lineage markers (Cytobank; settings: 1,000 iterations, 30 perplexity, and 0.5 theta). Representative tSNE plots are shown (see [Figure S5](#mmc1){ref-type="supplementary-material"} for all samples) and were colored by expression or phosphorylation of the indicated markers.(F) Left, percentages of CD5^+^CD19^+^ cells among all live cells are shown in untreated and treated PBMC samples. FdG, treatment with 2 μM forodesine and 20 μM dG. Right, the frequency of live CD5^+^CD19^+^ cells was set to 100 in untreated samples, and their percentage after forodesine and dG treatment is shown.(G--H) The staining for cleaved PARP (G) and cleaved CASPASE3 (H) in live CD5^+^CD19^+^ cells was analyzed. Left, median values are shown in untreated and treated cells. Right, median values from untreated cells were set to 100 separately for each sample.In (A), (C), (D), and (F)--(H), dots represent cells from different patients and the color indicates the mutation status (gray, *ATM* ; black, *TP53*; blue, *SAMHD1*). Horizontal bars represent means. In (C) and (D), box and whiskers show SD and maximum/minimum values, respectively. The p values determined with two-way ANOVA (A) or unpaired t test (C),(D), and (F)--(H) are indicated. ns, p ≥ 0.05; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001.See also [Figures S4--S6](#mmc1){ref-type="supplementary-material"}.

To investigate which types of cells were affected by exposure to forodesine and dG, we used cytometry by time of flight (CyTOF) analysis. PBMCs from healthy control subjects and patients with CLL were treated or not with both compounds. After treatment, cells were stained with a panel of antibodies recognizing cell surface markers to identify cell types. SAMHD1 expression, phosphorylation of nuclear factor κB (NF-κB)-p65, p38, and STAT1, and cleavage of PARP and CASPASE3 were also monitored by intracellular staining. CLL B cells were marked by co-expression of CD5 and CD19 ([@bib81]). As expected, CD5^+^CD19^+^ cells (CLL B cells) were largely absent from control PBMCs and could be detected at varying frequencies in samples from patients with CLL, irrespective of *SAMHD1* genotype ([Figures 5](#fig5){ref-type="fig"}B, 5C, [S4](#mmc1){ref-type="supplementary-material"}C, and S4D). We also analyzed SAMHD1 expression in CLL B cells. Variable expression of SAMHD1 was observed in the *SAMHD1* non-mutated group, while CLL B cells from the *SAMHD1*-mutated group had no detectable levels of SAMHD1 ([Figures 5](#fig5){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}C). This shows that the *SAMHD1* mutations studied here resulted in a loss of SAMHD1 protein, in line with our earlier observations ([@bib16]).

Next, we analyzed our CyTOF data using viSNE ([@bib3], [@bib46]). This analysis tool uses the t-Distributed Stochastic Neighbor Embedding (tSNE) algorithm and displays high-dimensional data on a two-dimensional map. Each dot on a viSNE plot corresponds to a cell. Color can be used to show the expression of a chosen parameter. We generated viSNE plots after gating on CLL B cells ([Figures 5](#fig5){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}). tSNE maps showed a marked reduction of CLL B cells upon forodesine and dG treatment in cells from *SAMHD1*-mutated patients, but not in the *SAMHD1* WT groups ([Figures 5](#fig5){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}). Gating on CLL B cells also confirmed that forodesine and dG treatment resulted in their selective loss in the *SAMHD1*-mutated group, while there was no effect on the same cell population in the *SAMHD1* non-mutated group ([Figure 5](#fig5){ref-type="fig"}F). Significantly increased levels of cleaved PARP and cleaved CASPASE3 were observed only in *SAMHD1-*mutated CLL B cells post-treatment, consistent with the induction of apoptosis ([Figures 5](#fig5){ref-type="fig"}G and 5H).

Interestingly, forodesine and dG ablated a subpopulation of *SAMHD1*-mutated CLL B cells, which appeared to be characterized by high levels of NF-κB-p65, p38, and STAT1 phosphorylation ([Figures 5](#fig5){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}). Using phosphorylated (p-)p38, a mitogen-activated protein (MAP) kinase, we defined "active" and "inactive" cells and analyzed the expression of selected markers in these subpopulations ([Figure S6](#mmc1){ref-type="supplementary-material"}A). This analysis confirmed that p-p38-positive cells also displayed higher levels of p-p65 and p-STAT1 and revealed higher levels of CD27 expression in these "active" cells, which may indicate engagement of the B cell receptor ([@bib49]). Interestingly, staining for cleaved PARP and cleaved CASPASE3 was enhanced more strongly in "inactive" cells upon treatment ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C). This suggests that these "inactive" CLL B cells were also affected by the treatment and induced apoptosis with delayed kinetics compared to "active" cells.

Collectively, these data show that forodesine and dG were highly efficient at killing malignant CLL B cells with *SAMHD1* mutations that cause a defect in SAMHD1 expression, while cells with intact SAMHD1 expression were spared.

Discussion {#sec3}
==========

Our data reveal an unexpected role of SAMHD1 in safeguarding cells against cell death resulting from imbalances in dNTP pools. In the absence of SAMHD1, dNTP imbalances induced by exposure of cells to dNs triggered apoptosis. This phenotype was observed in a wide range of human and mouse cells, including primary and transformed cells. We further show synergy between dG exposure and forodesine, which blocks dG degradation by PNP, in cells lacking SAMHD1. Importantly, the combination of dG and forodesine selectively killed SAMHD1-deficient CLL B cells, while other normal cells or SAMHD1-sufficient CLL B cells remained unaffected.

Since its identification as a restriction factor for HIV ([@bib41], [@bib50]), SAMHD1 has been studied extensively in the context of lentiviral infections. Interestingly, SAMHD1 is highly conserved from marine invertebrates to man ([@bib73]), whereas lentiviruses evolved much more recently. This suggests that restriction of lentiviral infection is an exaptation of SAMHD1's biochemical activity to degrade dNTPs, which perhaps has a more ancestral function in cellular dNTP metabolism. We propose that this evolutionarily conserved function of SAMHD1 is to correct imbalances in dNTP pools, thereby safeguarding against cell death. Indeed, we report that intracellular dNTP concentrations were only marginally altered in WT cells exposed to extracellular dNs, while SAMHD1-deficient cells accumulated large dNTP pools. Concomitantly, cells lacking SAMHD1 succumbed to apoptotic cell death.

Interestingly, dG was the most toxic dN. This may be related to the observation that baseline dGTP concentrations are lower than those of the three other dNTPs, resulting in particularly pronounced dNTP imbalances upon dG feeding. In addition, dGTP allosterically regulates ribonucleotide reductase, preventing dCTP production through the *de novo* pathway ([@bib60]). Consistent with this idea is our observation that the toxicity of dG was reduced when added together with dC, providing dCTP via the salvage pathway. In addition, dC may indirectly increase dTTP concentrations via a pathway involving dCMP deaminase and thymidylate synthase ([@bib82]), thereby balancing dNTP levels.

The molecular mechanism by which dNTP imbalances cause cell death is a long-standing question ([@bib31], [@bib57]), and future work will be required to elucidate how apoptosis is triggered in SAMHD1-deficient cells containing elevated dGTP pools. We observed release of cytochrome C from mitochondria into the cytosol, indicative of cell-intrinsic apoptosis. This notion was supported by the observation that cell death in mixed cultures containing WT and *Samhd1*^*−/−*^ cells was proportional to the fraction of knockout cells. We further found that dN-triggered cell death did not require ongoing nuclear DNA synthesis. It is therefore possible that dNTP imbalances disrupt replication or repair of mitochondrial DNA, resulting in mitochondrial stress and subsequent apoptosis ([@bib4], [@bib25]). dGTP may also be involved more directly in the activation of apoptosis, as has been reported for dATP ([@bib54], [@bib72]). Alternatively, dN treatment might have indirect effects on the induction of apoptosis in the absence of SAMHD1. Indeed, in THP1 cells, SAMHD1 knockout results in increased cell proliferation and altered cell cycle and apoptosis control ([@bib14]).

Clinical trials showed that forodesine has beneficial effects in some, but not all, patients with B or T cell malignancies ([@bib2], [@bib5], [@bib6], [@bib7], [@bib21], [@bib27], [@bib28], [@bib59], [@bib64]), an observation that thus far has lacked an explanation. This study and our earlier work shows that *SAMHD1* mutations found in patients with CLL often result in the loss of expression at mRNA and protein levels ([@bib16]). Importantly, our data suggest that forodesine-sensitive leukemias harbor mutations that ablate SAMHD1 expression. It is possible that *SAMHD1* mutations found in some patients with CLL do not affect SAMHD1 protein levels. We speculate that such mutations will sensitize cells to forodesine if they impair SAMHD1's dNTPase activity. It may therefore be possible to stratify patients by *SAMHD1* genotype, expression levels, or protein function. *SAMHD1* mutations are found in 3%--5% of newly diagnosed CLL and expand in relapsed and refractory disease to a frequency of about 11% ([@bib16], [@bib52]). As such, only a subset of patients with CLL is likely to benefit from forodesine. However, CLL is the most common leukemia in the Western world; thus, significant numbers of patients with CLL have *SAMHD1* mutations. Furthermore, *SAMHD1*-mutated cases show poorer response to conventional first-line chemoimmunotherapy compared to *SAMHD1* WT patients. Thus, the results presented here are highly relevant and clinically significant to expand choices of first-line treatments to this specific patient group ([@bib16]).

Retrospective analysis of previous clinical trials with forodesine could lend support to the idea of stratifying patients by SAMHD1 status. However, restricted sample availability, limited consent to obtain genetic information, and small trial sizes have precluded this approach. Instead, future clinical trials should be conducted to determine whether the efficacy of forodesine can be predicted by the presence or absence of SAMHD1 in transformed cells. Survival of PBMCs *ex vivo* upon forodesine and dG treatment ([Figure 5](#fig5){ref-type="fig"}A) and commercially available α-SAMHD1 antibodies would be suitable for rapid clinical assays to identify patients with SAMHD1 deficiency. Previous studies reported that dG needs to be added in combination with forodesine to induce toxicity *in vitro* ([@bib2], [@bib5], [@bib10], [@bib27], [@bib28]). In patients, forodesine treatment alone has been shown to increase plasma dG levels ([@bib5], [@bib6]). However, it may also be interesting to explore supplementing forodesine with dG in patients with leukemia with acquired *SAMHD1* mutations. It is noteworthy that SAMHD1 is broadly expressed in most normal human tissues ([@bib77], [@bib83]). As such, forodesine and dG are unlikely to have negative effects on healthy cells.

Our CyTOF analysis revealed that CLL B cells, identified by CD19 and CD5 staining, contained two subpopulations of cells, distinguishable by expression of CD27 and phosphorylation of p65, p38, and STAT1. Activation of NF-κB, MAP kinase, and STAT signaling pathways has been reported in CLL ([@bib24], [@bib32], [@bib74], [@bib80]), and CD27 is upregulated in response to B cell receptor engagement ([@bib49]). We therefore labeled these cell populations "active" and "inactive." Interestingly, we found that forodesine and dG not only killed the "active" population of CLL B cells, but also induced markers of apoptosis in the "inactive" cells. As such, forodesine may have an advantage over other CLL drugs that inhibit B cell receptor signaling and thus target only "active" cells.

In an independent line of investigations, SAMHD1 was found to not only degrade naturally occurring dNTPs, but also some nucleotide analogs, including cytarabine (ara-C) and decitabine (DAC), which are used for the treatment of acute myeloid leukemia (AML) ([@bib33], [@bib34], [@bib39], [@bib63], [@bib78]). The response of patients with AML to ara-C or DAC inversely correlates with SAMHD1 expression levels or activity ([@bib33], [@bib63], [@bib75], [@bib78]). These observations are an interesting parallel to our work and highlight SAMHD1 as a target for cancer therapy.

In summary, we uncovered an important role of SAMHD1 in protecting cells against dNTP imbalance that otherwise triggers apoptotic cell death. These findings allowed us to selectively ablate *SAMHD1*-mutated transformed cells that lacked SAMHD1 expression using a combination treatment involving forodesine and dG. In the future, forodesine may be developed into a precision medicine for a subset of patients with leukemia with acquired *SAMHD1* mutations.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-hSAMHD1 (mouse polyclonal)AbcamCat\# ab67820; RRID:[AB_2301350](nif-antibody:AB_2301350){#intref0010}Anti-mSAMHD1 (Rabbit)[@bib69]N/AAnti-mouse AF594 (goat)Life technologiesCat\# A-11005; RRID:[AB_141372](nif-antibody:AB_141372){#intref0015}Anti-Caspase 3Cell SignalingCat\# 9661T; RRID:[AB_2341188](nif-antibody:AB_2341188){#intref0020}Anti-cytochrome CBDCat\# 556433; RRID:[AB_396417](nif-antibody:AB_396417){#intref0025}Anti-β-actin HRPSigmaCat\# A3854; RRID:[AB_262011](nif-antibody:AB_262011){#intref0030}Anti-Rabbit HRPGE-HealthcareCat\# NA934V; RRID:[AB_772206](nif-antibody:AB_772206){#intref0035}Anti-Mouse HRPGE-HealthcareCat\# NA931V; RRID:[AB_772210](nif-antibody:AB_772210){#intref0040}Anti-gapdh HRPproteintechCat\# HRP-60004; RRID:[AB_2737588](nif-antibody:AB_2737588){#intref0045}Anti-COX IVCell SignalingCat\# 11967S; RRID:[AB_2797784](nif-antibody:AB_2797784){#intref0050}Anti-HA HRPCell SignalingCat\# 2999S; RRID:[AB_1264166](nif-antibody:AB_1264166){#intref0055}Anti-PARPCell SignalingCat\# 9542P; RRID:[AB_2160739](nif-antibody:AB_2160739){#intref0060}Anti-BrdU AF488BiolegendCat\# 364106; RRID:[AB_2564500](nif-antibody:AB_2564500){#intref0065}**Bacterial and Virus Strains**Biological SamplesHuman peripheral blood mononuclear cells (PBMCs)ADMIRE and ARCTIC studies ([@bib40], [@bib61])N/AHuman fibroblastsYanick Crow LaboratoryN/A**Chemicals, Peptides, and Recombinant Proteins**HydroxyureaSigmaCat\# H8627-5G2′-deoxyadenosine monohydrateSigmaCat\# D8668-1G2′-deoxythymidineSigmaCat\# T1895-1G2′ deoxyguanosineMedChemexpress LLCCat\# HY-175632′-deoxycytidine hydrochlorideMedChemexpress LLCCat\# HY-17564EtoposideSigmaCat\# E1383-25MGForodesine hydrochlorideMedChemexpress LLCCat\# HY-16209BenzonaseSigmaCat\# E8263-5KUYOYO-3 IodideLife technologiesCat\# Y3606PepsinSigmaCat\# 77160FxCycle PI/RNase Staining Solution-100 mLLife technologiesCat\# F10797Protease inhibitorsCell signalingCat\# 871SPhosphatase inhibitorsSigmaCat\# P0044Sample bufferLife technologiesCat\# NP0007Novex protein standardLife technologiesCat\# LC5800MOPS running bufferLife technologiesCat\# NP001MES running bufferLife technologiesCat\# NP001NuPAGE AntioxidantLife technologiesCat\# NP0005PonceauSigmaCat\# P7170Tween20SigmaCat\# P1379ECLPerkin ElmerCat\# NEL104001EAECL primeSigmaCat\# GERPN2232DigitoninLife technologiesCat\# BN2006Crystal violetSigmaCat\# HT90132Propidium iodideSigmaCat\# P41704-12% Bis Tris protein gelLife technologiesCat\# NP0321BOXFcR blockeBiosciencesCat\# 14-9161-73AphidicolinInsight Biotechnology LtdCat\# sc-201535MenadioneFluorochemCat\# 049845-1gMethoCultStemcell technologiesCat\# 04100GlutamaxThermofisherCat\# 35050061IMDMThermofisherCat\# 12440053PrimocinInvivogenCat\# ant-pm-1Anti-Annexin V AF488Life technologiesCat\# A13201**Critical Commercial Assays**FITC annexinV / 7AAD detection kitBiolegendCat\# 640922CellTiter-Glo Luminescent Cell Viability AssayPromegaCat\# G7571Caspase Glo 3/7PromegaCat\# G6320TaqMan Universal PCR Master MixThermofisherCat\# 4304437ROS-Glo H~2~O~2~ assayPromegaCat\# G8820**Deposited Data**CyTOF dataThis paperFlowRepository:\
[FR-FCM-Z2JH](https://flowrepository.org/id/FR-FCM-Z2JH){#interref0010}**Experimental Models: Cell Lines**Human: HeLa cellsMichael Way LaboratoryN/AHuman: MDA MB231 cellsAlison Banham LaboratoryN/AHuman: B16F10 cellsVincenzo Cerundolo LaboratoryN/AHuman: Jurkat cellsSimon Davis LaboratoryN/A**Experimental Models: Organisms/Strains**Mouse: *Samhd1*^*−/−*^: Samhd1^tm1.2Crs^[@bib69]RRID:MGI:5543265**Oligonucleotides**mSAMHD1 sgRNA1 fwd: CACCGgaggaactggtagctgtacaThis paperN/AmSAMHD1 sgRNA1 rvs: AAACtgtacagctaccagttcctcCThis paperN/AmSAMHD1 sgRNA 2 fwd: CACCgggtgaaccccaagctcttThis paperN/AmSAMHD1 sgRNA 2 rvs: AAACaagagcttggggttcacccThis paperN/APrimer 1 fwd: tgacagtttgcatctaacctctgThis paperN/APrimer 2 rvs: tgacagtttgcatctaacctctgThis paperN/APrimer 3 fwd: tgacagtttgcatctaacctctgThis paperN/A**Recombinant DNA**pSIV3+[@bib62]N/ApSIV4+[@bib62]N/ApCMV-VSVG[@bib69]N/ApCSHAwtW[@bib76]N/ApCSHAk11aW[@bib76]N/ApCSHAh233aW[@bib33]N/Ap8.91 (packaging plasmid)[@bib69]N/ApMSCVpuro-mSAMHD1This paperN/ApMSCVpuroClontechCat\# 634401pX458-Ruby[@bib35]N/ApX458[@bib68]Addgene Plasmid \#48138pX458-Ruby-sgRNA-1This paperN/ApX458-sgRNA-2This paperN/A**Software and Algorithms**Graph pad prism 7<https://www.graphpad.com>N/AFlowJo V10<https://www.flowjo.com>N/ACytobank<https://www.cytobank.org>N/A**Other**

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jan Rehwinkel (<jan.rehwinkel@imm.ox.ac.uk>).

### Materials Availability {#sec4.2.2}

All unique reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

### Data and Code Availability {#sec4.2.3}

The CyTOF data generated during this study are available at FLOWRepository: [FR-FCM-Z2JH](https://flowrepository.org/id/FR-FCM-Z2JH){#interref0015}. The authors declare that all other data supporting the findings of this study are available within the paper and its supplementary information files.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

Mice were housed and bred under standard conditions at the University of Oxford Biomedical Services Animal Facilities. *Samhd1*^*−/−*^ mice (C57BL/6N background) were described previously ([@bib69]). 8-12 week old, male and female C57BL/6N WT and *Samhd1*^*−/−*^ mice were used to obtain bone marrow for BMDM cultures.

### Cells {#sec4.3.2}

MEFs were made by standard protocols from either WT or *Samhd1*^*−/−*^ mice. Bone marrow cells were isolated by standard protocols and, to obtain BMDMs, were grown in Petri dishes for 7 days in R10 medium \[Roswell Park Memorial Institute 1640 (RPMI) medium, 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin and 100 μg/ml streptomycin (P/S), 2 mM L-Glutamine\] supplemented with 20% L929 conditioned medium and used on day 7. Human fibroblasts from AGS patients were provided by Y. Crow and G.I. Rice. MEFs were cultured in D10 medium \[Dulbecco's modified Eagle medium (DMEM) containing 10% heat-inactivated FCS, P/S, 2mM L-Glutamine and 20 mM HEPES buffer\]. Human fibroblasts, HeLa, B16F10 and MDA MB231 cells were cultured in D10 without P/S. HeLa cells were a gift from M. Way, MDA MB231 cells were from A. Banham and B16F10 cells were provided by V. Cerundolo. Jurkat cells were a gift from S. Davis and originate from the American Type Tissue Collection and were cultured in R10 without P/S. All cells were cultured under 5% CO~2~. Human fibroblasts and MEFs were cultured under low oxygen (1.2% O~2~).

### Samples from Patients with CLL {#sec4.3.3}

PBMCs from 14 patients with CLL recruited into the ADMIRE (n = 10) and ARCTIC (n = 4) studies ([@bib40], [@bib61]) were retrieved from the Liverpool Bio-Innovation Hub Biobank. Genetic characterization of the tumor cells for these patients was previously published ([@bib16]) and the patients' gender and age at sample collection are indicated in [Figure S4](#mmc1){ref-type="supplementary-material"}A. PBMCs were thawed in R10 with P/S and 50 U/ml of benzonase, washed twice before being counted and plated. For CellTiter-Glo assay, 50,000 cells were plated in U-bottom 96-well plates. CyTOF experiments were performed using 3,000,000 cells in 12-well non-coated tissue culture plates.

### Study Approval {#sec4.3.4}

Mouse work was performed in accordance with the UK Animals (Scientific Procedures) Act 1986 and institutional guidelines for animal care. This work was approved by a project license granted by the UK Home Office (PPL No. PC041D0AB) and also was approved by the Institutional Animal Ethics Committee Review Board at the University of Oxford.

Informed consent from all patients was obtained in line with the Declaration of Helsinki. The CLL work was covered by the Ethics approval REC 09/H1306/54. Human fibroblasts from patients with AGS were collected with approval by a UK Multicenter Research Ethics Committee (reference number 04:MRE00/19).

Method Details {#sec4.4}
--------------

### Plasmids {#sec4.4.1}

To generate pMSCVpuro-mSAMHD1, mouse *Samhd1* isoform 1 was PCR amplified. A kozak sequence and N-terminal 3xFLAG-tag were introduced by PCR and the PCR product was cloned into pMSCVpuro using the EcoRI site. To generate SAMHD1-deficient mouse cells, pX458-Ruby-sgRNA-1 and pX458-sgRNA-2 were cloned using pX458-Ruby and pX458, respectively, as described before ([@bib35]).

### dNTP Measurements {#sec4.4.2}

Cells from 4 plates (90 × 15 mm) of BMDMs or 3 plates (150 mm × 20 mm) of MEFs were pooled for each sample. Measurements were done on cells from different mice. Cells were treated with deoxynucleosides for a specific time and washed twice with ice-cold NaCl (9 g/L) on ice. Cells were then scraped in 550 μL of ice-cold trichloroacetic acid (15% w/v), MgCl~2~ (30mM) solution, collected into an Eppendorf tube, frozen on dry ice and stored at −80°C. Cells were thawed on ice and processed as described in [@bib47]. Briefly, the cell suspension was pulse-vortexed (Intellimixer) at 99 rpm for 10 min at 4°C and centrifuged at 20,000 × g for 1 min at 4°C. The resulting supernatant was then neutralized twice with Freon-Trioctylamine mix (78% v/v - 22%, v/v respectively) by vortexing for 30 s and centrifugation at 20,000 × g for 1 min. 475 μL of the aqueous phase was pH-adjusted with 1 M ammonium carbonate (pH 8.9), loaded on boronate columns (Affi-Gel Boronate Gel; Bio-Rad), and eluted with a 50 mM ammonium carbonate (pH 8.9) and 15 mM MgCl~2~ mixture to separate dNTPs from NTPs. The eluates containing dNTPs were adjusted to pH 4.5 and loaded onto an Oasis weak anion exchange (WAX) SPE cartridge. Interfering compounds were eluted off the cartridges in two steps with 1 mL ammonium acetate buffer (pH-adjusted to 4.5 with acetic acid) and 1 mL 0.5% ammonia aqueous solution in methanol (v/v), and the analytes were eluted from the cartridge with 2 mL methanol/water/ammonia solution (80/15/5, v/v/v) into a glass tube and then evaporated to dryness using a centrifugal evaporator at a temperature below 37°C. The residue was reconstituted in 1250 μL ammonium bicarbonate buffer, pH-adjusted to 3.4 and used for the HPLC analysis as described in [@bib43]. Briefly, nucleotides were isocratically eluted using 0.36 M ammonium phosphate buffer (pH 3.4, 2.5% v/v acetonitrile) as mobile phase. dNTPs were normalized to total NTP pool of the cells.

### Viability Assays {#sec4.4.3}

CellTiter-Glo (Promega), a luminescence assay that measures ATP levels, was used according to manufacturer instructions to assess viability. To assess cell viability with crystal violet, cells were stained with 0.5% crystal violet for 20 min, washed 3 times with water and dried overnight before being resuspend in 200 μL methanol and absorbance was measured at 570 nm as described in [@bib23]. For analysis of cell death with the Incucyte live-cell analysis system (Sartorius), Yoyo3 iodide viability die was used at 1/8000 final concentration and images were acquired. The Incucyte was also used to measure confluency and acquire bright-field images over time with a 10x objective.

### Apoptosis Assays {#sec4.4.4}

The Annexin V/7AAD kit was used to detect apoptotic cells by flow cytometry according to the manufacturer's protocol. Caspase 3/7 Glo (Promega) was used to measure caspase 3/7 cleavage. For live cell imaging, BMDMs were cultured in a glass chamber coated with Poly-L-lysine at 37°C and 5% CO~2~. Culture media were supplemented with 2.5mM CaCl~2~, 20 mM HEPES, propidium iodide (3 μl/well) and Annexin V AF488 (1 μl/well). Images were acquired with a Delta Vision microscope with 10x objective lens every 10 minutes for 24 hours.

### Cell Cycle Analysis {#sec4.4.5}

BMDMs were seeded at 10^6^ cells/well in 6-well low attachment plates and were incubated with 10 μM BrdU for 30 min. In pulse chase experiments, cells were incubated with 10 μM BrdU for 15 min, the media was then replaced, and cells were exposed to dG. At appropriate time points, cells were washed and fixed in 70% ethanol and frozen at −20°C. Cells were washed and resuspend in pepsin solution (1 mg/ml in 30 mM HCl) for 30 min at 37°C, spun down and resuspend in 2M HCl for 15 min at room temperature (RT) and washed with PBS. Cells were then blocked with 0.5% BSA, 0.5% Tween-20 in PBS for 30 min at room temperature, washed and resuspend in FACS buffer with α-BrdU AF488 antibody at 1:100 dilution for 30 min at room temperature. Fix Cycle PI/RNase A staining solution was added to the cells for 30 min at RT. Cells were acquired on a BD LSR II flow cytometer.

### Clonogenic Assay {#sec4.4.6}

Jurkat cells were treated with dG for 20 hours in IMDM with 10% FCS. 1200 cells were then seeded per well in 6 well plates in methylcellulose, semi-solid medium (40% MethoCult, 39% IMDM, 20% FCS, 1% glutamax and primocin at 100 μg/ml) containing dG. After 13 days incubation, cell colonies were counted manually.

### Measurement of ROS Production {#sec4.4.7}

H~2~O~2~ production was measured using the ROS-Glo H~2~O~2~ assay (Promega) according the manufacturer's instructions.

### Western Blots {#sec4.4.8}

Cells were lysed in NP-40 buffer (150 mM NaCl, 1% NP-40, 50 mM Tris pH 8.0) with protease and phosphatase inhibitors. After 20 min incubation on ice, lysates were centrifuged at 17,000 g for 10 min at 4°C. Supernatant was collected and diluted with sample buffer before denaturation at 94°C for 5 min. Samples were loaded on pre-cast 4%--12% gradient Bis-Tris protein gels that were run with MOPS or MES buffer at 120 V for 2 hours. Transfer to nitrocellulose membranes was performed in transfer buffer (25mM Tris, 192mM glycine, 20% methanol) at 30 V for 3.5 hours. Membranes were blocked in 5% milk powder in Tris buffered saline with 1% Tween-20 (TBST) for 1 hour at room temperature then washed 5 times for 5 min in TBST. Membranes were incubated with primary antibody in 5% milk TBST overnight at 4°C, then washed 5 times for 5 min in TBST. ECL or ECL prime substrates were used for signal detection. In some experiments, membranes were stripped (0.2 M glycine, 0.1% SDS at pH 2.5) for 15 minutes, washed, blocked, and re-probed with a different antibody.

### Retroviral Vectors {#sec4.4.9}

VSV-G-pseudotyped retroviral vectors were produced by plasmid transfection of 293T cells ([@bib15]). Retroviral infections were performed in the presence of 8 μg/ml polybrene. Bone marrow cells were transduced three times by spin-infection (2500 rpm, 120 min, 32°C, no brakes) on days 1, 2 and 3 of the 7-day differentiation process with the retroviral vector expressing SAMHD1 or a control vector. Cells were seeded into new plates on day 7 and treated with dG on the next day. THP1 cells were transduced by spin infection (2500 rpm, 120 min, 32°C, no brakes), seeded and treated as indicated in the figure legends. Jurkat cells, MDA-MB231 and HeLa cells were transduced by adding viral vectors to the culture medium. VLP~vpx~ and VLP~ctrl~ were generated using the SIVmac gag-pol expression vectors SIV3+ and SIV4+ ([@bib56]). Human SAMHD1 expression constructs pCSHAwtW, pCSHAk11aW and pCSHAh233aW were a kind gift from T. Schaller. These were used to generate lentiviruses for reconstitution of Jurkat cells ([@bib15]). Mouse SAMHD1 expression construct pMSCVpuro-mSAMHD1 was used to generate a retroviral vector to transduce bone marrow cells as described earlier ([@bib69]).

### Stimulation, Staining, and Mass Cytometry Analysis of Patient Samples {#sec4.4.10}

PBMCs were collected 24 hours after treatment with forodesine and dG, and were processed according to the Fluidigm Maxpar protocol, using Maxpar reagents. Antibodies are listed in the [Table S1](#mmc1){ref-type="supplementary-material"}. Cells were collected in 15 mL falcon tubes and were washed in PBS, using centrifugation at 300 g for 5 min. Cells were resuspend at 10^7^/ml in R0 with Cisplatin (1:10,000) and incubated at 37°C for 5 minutes. Cells were washed with R10 and resuspend in Maxpar PBS. Staining was performed on 3^∗^10^6^ cells/tube. Staining with CD56, CD27, CCR4 and CCR7 was done before fixation. Cells were fixed with Maxpar Fix I Buffer at room temperature (RT) for 10 min then washed with Maxpar Cell Staining Buffer (CSB) and spun at 800 g for 5 min. Cells were barcoded (fluidigm barcoding kit) for 30 min at RT, washed twice in CSB, pooled and counted. All further steps were performed on the pooled sample. Cells were blocked in FcR block diluted in CSB (1:10) for 10 min at RT. Surface staining antibody mix was added to blocking solution and incubated for 30 min at RT. Cells were washed in CSB, resuspend in ice cold methanol added dropwise under the vortex and stored at −80°C overnight. Cells were washed twice with CSB and stained with the intracellular antibody mix for 30 min at RT and stained with intercalator overnight. Next day they were washed with CSB and resuspend in water before acquisition on the Helios mass cytometer (Fluidigm). Samples were normalized, concatenated, and de-barcoded using Helios software. Files were analyzed with Cytobank.

### Generation of Samhd1^−/−^ B16F10 Cells {#sec4.4.11}

sgRNAs were designed to excise exon 2 of mouse *Samhd1* (Gene ID: 56045). Exon 2 is critical to both isoforms of *Samhd1* (see [Figure S2](#mmc1){ref-type="supplementary-material"}D and [@bib69]). B16F10 cells were co-transfected with pX458-Ruby-sgRNA-1 and pX458-sgRNA-2 plasmids. GFP-Ruby double positive cells were single cell sorted and clones were expanded. A PCR screening approach was used to identify knock-out cells. PCR-1 was designed to amplify a long fragment (709 bp) from the WT allele and a short fragment (350 bp) from the KO allele using primer 1 fwd and primer 2 rvs (see [Figure S2](#mmc1){ref-type="supplementary-material"}D). PCR-2 had a primer located in exon 2 and amplified a fragment (352 bp) only from the WT allele using primer 2 rvs and primer 3 fwd ([Table S1](#mmc1){ref-type="supplementary-material"}).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

All experiments were performed three times or more independently under similar conditions, unless specified otherwise in figure legends. Statistical significance was calculated by unpaired t test, one-way ANOVA or two-way ANOVA as described in the figure legends; p \< 0.05 was considered significant. Graph pad prism 7 software was used to generate graphs and to perform statistical analysis.
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Document S1. Figures S1--S6 and Table S1Document S2. Article plus Supplemental Information
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